Zoetis Inc. with ticker code (ZTS) have now 11 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $255.00 and $190.00 suggesting an average Analsyt target price of $216.18. Given that the stocks previous close was at $179.65 and the analysts are correct then there would likely be a percentage uptick in value of 20.3%. The 50 day MA is $171.37 and the 200 day MA is $174.22. The company has a market capitalization of 83.56B. The stock price for the company is currently $182.00 USD
The potential market cap would be $100,549,564,663 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 37.07, revenue per share of $18.09 and a 13.76% return on assets.
Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. It commercializes products across eight core species: dogs, cats and horses and cattle, swine, poultry, fish and sheep and within product categories, such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The Company operates through two segments: the United States and International. Within each of these operating segments, it offers a product portfolio for both companion animal and livestock customers. The Company market its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company’s products are sold in more than 100 countries.
